<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04181385</url>
  </required_header>
  <id_info>
    <org_study_id>OLA 15-8951</org_study_id>
    <nct_id>NCT04181385</nct_id>
  </id_info>
  <brief_title>Acute Olanzapine and Lipid Response</brief_title>
  <acronym>OLA</acronym>
  <official_title>Assessment of Lipid Response to Acute Olanzapine in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atypical antipsychotics are pharmaceutical drugs used to treat schizophrenia. Common side&#xD;
      effects are weight gain, insulin resistance, and abnormal blood lipids. This increases the&#xD;
      risk for type 2 diabetes and cardiovascular disease in patients taking these drugs. In&#xD;
      particular, olanzapine is a highly effective therapy for schizophrenia but is commonly&#xD;
      associated with metabolic disturbances. It has previously been shown that the negative&#xD;
      effects on insulin sensitivity and glucose metabolism occur even after a single dose,&#xD;
      independently of weight gain. These effects may be mediated by blocking the dopamine (D2)&#xD;
      receptor. In this study the research team is investigating whether a single dose of&#xD;
      olanzapine alters postprandial lipid metabolism after a high-fat drink. Olanzapine&#xD;
      administered along with the high-fat drink will be compared to placebo or olanzapine plus&#xD;
      bromocriptine (an activator of the D2 receptor).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postprandial lipid and hormonal responses are being investigated in up to 15 individuals.&#xD;
      Participants are their own control in a single-blind, placebo-controlled, crossover design.&#xD;
      Participants are admitted after an overnight fast. Participants will consume a high-fat drink&#xD;
      (50g of fat) along with either oral placebo, olanzapine (10mg) or olanzapine (10mg) plus&#xD;
      bromocriptine (5mg). Study visits occur 2-4 weeks apart with the three treatments applied in&#xD;
      random order. Blood samples will be taken at baseline and regular intervals after the&#xD;
      treatments for up to 8 hours to measure glucose, insulin, triglycerides, fatty acids and&#xD;
      other hormones/metabolites.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Participants receive either placebo, olanzapine or olanzapine plus bromocriptine, in random order on 3 separate study visits, with blood samples taken before and after treatment and intake of a high-fat drink</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Single-blinded study with participant blinded to treatment</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma triglycerides</measure>
    <time_frame>8 hours</time_frame>
    <description>Plasma triglycerides measured after treatments</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma fatty acids</measure>
    <time_frame>8 hours</time_frame>
    <description>Plasma fatty acids measured after treatments</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Olanzapine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olanzapine, 10mg, oral, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olanzapine plus bromocriptine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olanzapine, 10mg, oral, single dose Bromocriptine, 5mg, oral, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, oral, single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine 10 milligram</intervention_name>
    <description>Oral olanzapine capsule</description>
    <arm_group_label>Olanzapine</arm_group_label>
    <arm_group_label>Olanzapine plus bromocriptine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bromocriptine 5 milligram</intervention_name>
    <description>Oral bromocriptine capsule</description>
    <arm_group_label>Olanzapine plus bromocriptine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>oral placebo capsules</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women, aged 18 to 60 years&#xD;
&#xD;
          -  Body mass index (BMI) 20 to 40 kg/m2&#xD;
&#xD;
          -  Hemoglobin in the normal range.&#xD;
&#xD;
          -  Normal glucose tolerance in response to a 75 gram, 2-hr oral glucose tolerance test&#xD;
&#xD;
          -  Women of reproductive age should be on contraception (oral contraceptive pill or&#xD;
             intra-uterine device/coil) for at least 2 months prior to and after the study. Anyone&#xD;
             with a positive urine pregnancy test (carried out at screening and the day before each&#xD;
             kinetic study) will be excluded.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any volunteer with evidence of prolonged corrected QT interval (&gt;470 ms in males and&#xD;
             &gt;450ms in females)&#xD;
&#xD;
          -  Any volunteer with morbid obesity (BMI&gt;40 or BMI&gt;30 with any obesity related medical&#xD;
             complication such as diabetes, hypertension or coronary disease)&#xD;
&#xD;
          -  Any history of a myocardial infarction or clinically significant, active,&#xD;
             cardiovascular history including a history of arrhythmia's or conduction delays on&#xD;
             echocardiogram, unstable angina, or decompensated heart failure&#xD;
&#xD;
          -  Study participant with a history of hepatic disease that has been active within the&#xD;
             previous two years.&#xD;
&#xD;
          -  Any current or previous history of biliary disease (including gall stones, biliary&#xD;
             atresia and cholecystitis) or pancreatitis.&#xD;
&#xD;
          -  Any current or previous history of endocrine disease, dyslipidemia or malignancy&#xD;
&#xD;
          -  Any significant active (over the past 12 months) disease of the gastrointestinal,&#xD;
             pulmonary, neurological, renal (Cr &gt; 1.5 mg/dL) genitourinary, hematological systems,&#xD;
             or has severe uncontrolled treated or untreated hyper/ hypotension (sitting diastolic&#xD;
             BP &gt; 100 or systolic &gt; 180 or systolic BP&lt;100) or proliferative retinopathy&#xD;
&#xD;
          -  Use of immunosuppressive agents at any time during the study&#xD;
&#xD;
          -  Allergy to any study medication&#xD;
&#xD;
          -  Pregnancy (as ascertained by urinary human chorionic gonadotropin at screening and the&#xD;
             day before each study visit) or breastfeeding&#xD;
&#xD;
          -  Fasting blood glucose &gt; 6.0 mmol/l or known diabetes.&#xD;
&#xD;
          -  Any laboratory values: aspartate aminotransferase &gt; 2x upper limit of normal (ULN);&#xD;
             alanine transaminase &gt;2x ULN thyroid stimulating hormone &gt; 6 mU/l&#xD;
&#xD;
          -  Current addiction to alcohol or substances of abuse as determined by the investigator&#xD;
             or of any mental illness.&#xD;
&#xD;
          -  Mental incapacity, unwillingness or language barrier precluding adequate understanding&#xD;
             or cooperation&#xD;
&#xD;
          -  Taking any regular prescription or non-prescription medications at the time of the&#xD;
             study. Occasional use of medications such as acetaminophen or Tylenol 1 or any use of&#xD;
             natural health products may be permitted at the discretion of the investigator.&#xD;
&#xD;
          -  Will not donate blood three months prior to and three months post study procedures&#xD;
&#xD;
          -  Hemoglobin below the reference range (less than 130 g/l for males and 120 g/l for&#xD;
             females) based on blood tests at screening and on the day before the kinetic study&#xD;
&#xD;
          -  Hematocrit below the reference range (less than 0.38 for males and 0.37 for females)&#xD;
             based on blood tests at screening and on the day before the kinetic study&#xD;
&#xD;
          -  Soy allergy (component of high-fat drink)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Satya Dash, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Priska Stahel, PhD</last_name>
    <phone>416-581-7487</phone>
    <email>priska.stahel@uhn.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Satya Dash, MD</last_name>
    <phone>416-340-4800</phone>
    <phone_ext>8094</phone_ext>
    <email>satya.dash@uhn.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Priska Stahel, PhD</last_name>
      <phone>416-581-7487</phone>
      <email>priska.stahel@uhn.ca</email>
    </contact>
    <contact_backup>
      <last_name>Satya Dash, MD</last_name>
      <phone>416-340-4800</phone>
      <phone_ext>8094</phone_ext>
      <email>satya.dash@uhn.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 25, 2019</study_first_submitted>
  <study_first_submitted_qc>November 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2019</study_first_posted>
  <last_update_submitted>December 2, 2019</last_update_submitted>
  <last_update_submitted_qc>December 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>olanzapine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bromocriptine</mesh_term>
    <mesh_term>Olanzapine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

